TXG Relative Valuation
TXG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TXG is overvalued; if below, it's undervalued.
Historical Valuation
10X Genomics Inc (TXG) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.13 is considered Undervalued compared with the five-year average of -113.35. The fair price of 10X Genomics Inc (TXG) is between 21.27 to 138.12 according to relative valuation methord. Compared to the current price of 12.29 USD , 10X Genomics Inc is Undervalued By 42.23%.
Relative Value
Fair Zone
21.27-138.12
Current Price：12.29
42.23%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.76
P/B
Median3y
5.09
Median5y
11.16
3.65
FCF Yield
Median3y
-1.66
Median5y
-1.53
Competitors Valuation Multiple
The average P/S ratio for TXG's competitors is 8.94, providing a benchmark for relative valuation. 10X Genomics Inc Corp (TXG) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 9.84%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is 10X Genomics Inc (TXG) currently overvalued or undervalued?
What is 10X Genomics Inc (TXG) fair value?
How does TXG's valuation metrics compare to the industry average?
What is the current P/B ratio for 10X Genomics Inc (TXG) as of Jul 19 2025?
What is the current FCF Yield for 10X Genomics Inc (TXG) as of Jul 19 2025?
What is the current Forward P/E ratio for 10X Genomics Inc (TXG) as of Jul 19 2025?